KR20220159948A - 재발된 및/또는 불응성 다발 골수종의 치료를 위한 이사툭시맙의 용도 - Google Patents

재발된 및/또는 불응성 다발 골수종의 치료를 위한 이사툭시맙의 용도 Download PDF

Info

Publication number
KR20220159948A
KR20220159948A KR1020227023019A KR20227023019A KR20220159948A KR 20220159948 A KR20220159948 A KR 20220159948A KR 1020227023019 A KR1020227023019 A KR 1020227023019A KR 20227023019 A KR20227023019 A KR 20227023019A KR 20220159948 A KR20220159948 A KR 20220159948A
Authority
KR
South Korea
Prior art keywords
antibody
seq
amino acid
acid sequence
cdr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227023019A
Other languages
English (en)
Korean (ko)
Inventor
마리-로르 리세
가엘르 아세
Original Assignee
사노피-아벤티스 유.에스. 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 사노피-아벤티스 유.에스. 엘엘씨 filed Critical 사노피-아벤티스 유.에스. 엘엘씨
Publication of KR20220159948A publication Critical patent/KR20220159948A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Ceramic Products (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
KR1020227023019A 2019-12-06 2020-12-04 재발된 및/또는 불응성 다발 골수종의 치료를 위한 이사툭시맙의 용도 Pending KR20220159948A (ko)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201962944809P 2019-12-06 2019-12-06
US62/944,809 2019-12-06
EP20315186.5 2020-04-17
EP20315186 2020-04-17
US202063023198P 2020-05-11 2020-05-11
US63/023,198 2020-05-11
US202063037353P 2020-06-10 2020-06-10
US63/037,353 2020-06-10
US202063094833P 2020-10-21 2020-10-21
US63/094,833 2020-10-21
PCT/US2020/063468 WO2021113754A1 (en) 2019-12-06 2020-12-04 Use of isatuximab for the treatment of relapsed and/or refractory multiple myeloma

Publications (1)

Publication Number Publication Date
KR20220159948A true KR20220159948A (ko) 2022-12-05

Family

ID=74046182

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227023019A Pending KR20220159948A (ko) 2019-12-06 2020-12-04 재발된 및/또는 불응성 다발 골수종의 치료를 위한 이사툭시맙의 용도

Country Status (13)

Country Link
US (1) US20210171653A1 (cg-RX-API-DMAC10.html)
EP (1) EP4069740A1 (cg-RX-API-DMAC10.html)
JP (2) JP7704751B2 (cg-RX-API-DMAC10.html)
KR (1) KR20220159948A (cg-RX-API-DMAC10.html)
CN (1) CN115698065A (cg-RX-API-DMAC10.html)
AU (1) AU2020398655A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022010907A2 (cg-RX-API-DMAC10.html)
CA (1) CA3164026A1 (cg-RX-API-DMAC10.html)
CO (1) CO2022009433A2 (cg-RX-API-DMAC10.html)
IL (1) IL293615A (cg-RX-API-DMAC10.html)
MX (1) MX2022006883A (cg-RX-API-DMAC10.html)
TW (2) TWI887310B (cg-RX-API-DMAC10.html)
WO (1) WO2021113754A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4536278A4 (en) 2022-06-07 2026-08-12 Actinium Pharmaceuticals Inc CHELETARIANS AND BIFUNCTIONAL CONJUGATES

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
SG10201913777XA (en) * 2013-03-13 2020-03-30 Sanofi Sa Compositions comprising anti-cd38 antibodies and carfilzomib
MX373301B (es) * 2013-10-31 2020-04-24 Sanofi Sa Anticuerpos anti-cd38 específicos para usarse para tratar cánceres humanos.
US11618787B2 (en) * 2017-10-31 2023-04-04 Janssen Biotech, Inc. Methods of treating high risk multiple myeloma

Also Published As

Publication number Publication date
MX2022006883A (es) 2022-11-08
JP7704751B2 (ja) 2025-07-08
JP2025138745A (ja) 2025-09-25
WO2021113754A1 (en) 2021-06-10
TWI887310B (zh) 2025-06-21
TW202610683A (zh) 2026-03-16
BR112022010907A2 (pt) 2022-10-18
CO2022009433A2 (es) 2022-07-29
JP2023505219A (ja) 2023-02-08
AU2020398655A1 (en) 2022-07-28
TWI922320B (zh) 2026-04-11
EP4069740A1 (en) 2022-10-12
US20210171653A1 (en) 2021-06-10
CN115698065A (zh) 2023-02-03
TW202133880A (zh) 2021-09-16
IL293615A (en) 2022-08-01
CA3164026A1 (en) 2021-06-10

Similar Documents

Publication Publication Date Title
JP7573062B2 (ja) がん治療における化学療法剤と組み合わせた抗fgfr2抗体
JP7712206B2 (ja) 多発性骨髄腫の処置方法
US20200024344A1 (en) Compositions and methods for treating immune thrombocytopenia
CN118924895A (zh) 用于癌症治疗的结合her2、nkg2d和cd16的多特异性结合蛋白的药物制剂和剂量方案
KR20220159947A (ko) 피하 투여를 위한 항-cd38 항체의 제형
KR20220008305A (ko) 다발성 골수종을 치료하기 위해서 항-cd38 항체를 투여하는 방법
TW202342096A (zh) 靶向dll3的癌症治療
JP2022529502A (ja) 抗cd38抗体および製剤
JP2025138745A (ja) 再発性および/または不応性の多発性骨髄腫の処置のためのイサツキシマブの使用
TW202541838A (zh) 抗cd38抗體在治療新診斷的多發性骨髓瘤中之用途
KR20250029015A (ko) 다발성 골수종의 치료를 위한, 다른 제제와 조합된 이사툭시맙의 용도
RU2858309C2 (ru) Применение изатуксимаба для лечения рецидивирующей и/или рефрактерной множественной миеломы
CN116209468A (zh) 使用抗cd73和抗pd-l1抗体和化疗的治疗方法
RU2838203C2 (ru) Способы лечения множественной миеломы
CA3048198A1 (en) Methods of treating multiple myeloma
HK40109234A (en) Methods and compositions for treating cancer
TW202436335A (zh) 治療表現dll3的癌症之方法
WO2025094087A1 (en) Safe administration of a2a rector antagonist
TW202304981A (zh) 抗il-27抗體及其用途

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000